secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001437749-26-003575
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio reports 85% pathological response in highest dose cohort of PH-762 Phase 1b trial; no serious adverse events
--------------------------------------------------------------------------------

- No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.
- 85% pathological response (6/7 patients) in final cohort; 4 of 6 responders had complete tumor clearance.
- Overall response rate of 65% for squamous cell carcinomas (13/20 pathologic responders, including 9 complete).
- FDA submission for next-step guidance targeted for Q2 2026; cGMP manufacturing expected in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926003575/0001437749-26-003575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926003575/phio20260206_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-003575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer